Tag Archive for: EZH2 inhibitor
Mevrometostat Update: Phase 2 Clinical Trial Keeps Showing Promising Results
/0 Comments/in Clinical Trial, Metastatic, Phase 2/by MaxUpdate Phase 1: Mevrometostat Shows Promise in Prostate Cancer by Targeting EZH2
/0 Comments/in Clinical Trial, Metastatic, Phase 1/by MaxPhase III Trial for Metastatic Castration-Resistant Prostate Cancer of an EZH2 inhibitor
/0 Comments/in Clinical Trial, Metastatic, Phase 3/by MaxProject Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
225Ac abiraterone acetate ADC AI ai in healthcare alphafold antibody-drug conjugate apalutamide ASCO 2025 ATM bispecific antibody bone metastases bone metastasis BRCA BRCA2 cancer immunotherapy CAR-T clinical trial clinical trials crispr CYP11A1 inhibitor darolutamide drug repurposing drug resistance enzalutamide EZH2 inhibitor HRR immune checkpoint inhibitors immunotherapy mcrpc metastatic castration-resistant prostate cancer metastatic hormone-sensitive prostate cancer mHSPC mRNA NEPC neuroendocrine prostate cancer olaparib oncolytic virus personalized medicine prostate cancer PSMA radioligand therapy radiopharmaceuticals real-world data theranostics
Latest Posts
- Triplet therapy shows strongest survival benefit in mHSPC with visceral disease July 14, 2025
- Newsletter 28/2025 July 13, 2025
- New Combination Therapy Gets Fast Tracked: 177Lu-PSMA-617 (Pluvicto) Plus TRE-515 July 10, 2025
- A New Dug Delivery Platform is Being Released July 10, 2025